Vaxart Balance Sheet Health

Financial Health criteria checks 5/6

Vaxart has a total shareholder equity of $68.4M and total debt of $4.9M, which brings its debt-to-equity ratio to 7.1%. Its total assets and total liabilities are $166.7M and $98.2M respectively.

Key information

7.1%

Debt to equity ratio

US$4.88m

Debt

Interest coverage ration/a
CashUS$58.71m
EquityUS$68.44m
Total liabilitiesUS$98.23m
Total assetsUS$166.67m

Recent financial health updates

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Ray Stapleton joins Vaxart as CTO

Aug 31

Vaxart shareholders approve proposal to increase number of shares

Aug 05

Vaxart continues to lobby shareholders to vote to increase number of shares

Jul 29

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Financial Position Analysis

Short Term Liabilities: VXRT's short term assets ($66.5M) do not cover its short term liabilities ($80.4M).

Long Term Liabilities: VXRT's short term assets ($66.5M) exceed its long term liabilities ($17.9M).


Debt to Equity History and Analysis

Debt Level: VXRT has more cash than its total debt.

Reducing Debt: VXRT's debt to equity ratio has reduced from 98.4% to 7.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VXRT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VXRT has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 29.2% each year.


Discover healthy companies